HIV

The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Learn how retail or specialty pharmacy distribution can affect access to these important drugs.
[[thumbnail_alt_text]]
Following the global impact of COVID-19 on the health care system in 2020, there have been some clear changes in HIV care in the United States.
[[thumbnail_alt_text]]
Successfully implementing HIV and hepatitis C testing at drug detoxification centers could help identify and link patients to care, but would require that the test results are available to nearby health care facilities.
 
[[thumbnail_alt_text]]
Although antiretroviral therapy is an important option for patients with HIV, the viral reservoir has been a major obstacle for researchers looking to effectively cure the disease.
 
[[thumbnail_alt_text]]
According to results from a recent study, a functional cure for HIV may lie in identifying the viral reservoirs in which HIV places copies of its viral genetic material into cell genomes.
[[thumbnail_alt_text]]
According to the study authors, with a higher antigen valency, antibodies have more sites to latch onto; however, including a higher antigen valency in a vaccine does not mean it will work better.
[[thumbnail_alt_text]]
Antiretroviral therapy’s limitations lead to new efforts to treat the virus by neutralizing antibodies.
[[thumbnail_alt_text]]
Despite, antiretroviral therapy, HIV can hide in blood and tissue. 
[[thumbnail_alt_text]]
Fingolimod (Gilenya), which is approved by the FDA to treat multiple sclerosis flare-ups, may also block HIV and reduce the latent reservoir.
[[thumbnail_alt_text]]
A new study found that it’s safe for patients with HIV to receive HIV-positive kidneys. 
[[thumbnail_alt_text]]
As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.
[[thumbnail_alt_text]]
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.